BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;68:847-53. [PMID: 30633108 DOI: 10.1097/MPG.0000000000002265] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Reference Citation Analysis]
2 Kolho KL. Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease. Front Pediatr 2020;8:623689. [PMID: 33520903 DOI: 10.3389/fped.2020.623689] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 van Hoeve K, Seyed Tabib NS, Dreesen E, Tops S, Hoffman I, Gils A, Ferrante M, Vermeire S. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy. J Pediatr 2022;240:150-157.e4. [PMID: 34481805 DOI: 10.1016/j.jpeds.2021.08.079] [Reference Citation Analysis]
4 Moore H, Dolce P, Devas N, Baldassano R, Martinelli M. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis. United European Gastroenterol J 2020;8:425-35. [PMID: 32213038 DOI: 10.1177/2050640620912877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
6 Constant BD, Khushal S, Jiang J, Bost JE, Chaisson E, Conklin LS. Early Inflammatory Markers are Associated With Inadequate Post-Induction Infliximab Trough in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr 2021;72:410-6. [PMID: 33439565 DOI: 10.1097/MPG.0000000000002975] [Reference Citation Analysis]
7 Kapoor A, Crowley E. Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:661536. [PMID: 34123968 DOI: 10.3389/fped.2021.661536] [Reference Citation Analysis]
8 Pękala A, Filip R. Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis-A Prospective Polish Population Study. J Clin Med 2021;10:5311. [PMID: 34830598 DOI: 10.3390/jcm10225311] [Reference Citation Analysis]
9 Di Paolo A, Luci G. Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Front Pharmacol 2020;11:610806. [PMID: 33628180 DOI: 10.3389/fphar.2020.610806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]